BEAM vs. 90-Yttrium Ibritumomab Tiuxetan (Zevalin®)/BEAM With ASCT for Relapsed DLBCL

PRIMARY OBJECTIVES: I. To compare overall survival (OS) between the two transplant arms, with
at least a two year of follow-up. SECONDARY OBJECTIVES: I. To compare progression-free
survival (PFS), complete response (CR) and partial response (PR) proportion at day 100, time
to hematopoietic recovery, incidence of infection, grade III-IV toxicities, treatment-related
mortality, incidence of myelodysplastic syndrome (MDS), and secondary acute myelogenous
leukemia (AML).

OUTLINE: Patients are randomized to 1 of 2 treatment arms. ARM I: Patients receive rituximab
intravenously (IV) on days -21 and -14, and 90-yttrium ibritumomab tiuxetan IV on day -14.
Patients also receive BEAM comprising carmustine IV over 4 hours on day -6; cytarabine IV
over 2 hours twice daily (BID) on days -5 to -2; etoposide IV over 1 hour BID or once daily
(QD) on days -5 to -2; and melphalan IV on day -1. Patients then undergo peripheral blood
stem cell (PBSC) transplant on day 0. ARM II: Patients receive BEAM as in Arm I and undergo
PBSC transplant on day 0.

After completion of study treatment, patients are followed up weekly for 30 days, 100 days, 6
months, 1 year, every 3 months for 1 year, and then annually for 3 years.

Inclusion Criteria:

1. Patients with CD20 positive diffuse large B-cell lymphoma as confirmed by a
pathological biopsy report.

2. Patients who are candidates for autologous stem-cell transplantation due to primary
refractory or first relapse of disease.

3. Patients must have chemo-sensitive disease achieving at least partial response (Cheson
2007 criteria) to last chemotherapy.

4. Patients with adequate autologous stem cell collection for transplantation (target >=
2.5 x 10^6 CD34+ cells/kg).

5. Patients must sign written informed consent.

6. Adequate birth control in fertile patients.

7. All prior chemotherapy completed at least three weeks before study treatment.

8. Marrow involvement less than 25% at transplantation, no limitation on blood counts
(low platelet count allowed).

9. Negative HIV antibody.

Exclusion Criteria:

1. Chemo-refractory disease as determined by less than partial response (Cheson 2007
Criteria) to last chemotherapy.

2. Two or more relapses after initial response to induction chemotherapy.

3. High-grade transformation from earlier diagnosis of low-grade lymphoma. Patients with
"De Novo" Transformed DLBCL, defined as DLBCL only on lymph node biopsy and a
discordant marrow with para-trabecular small cells at first diagnosis of lymphoma, are
eligible if adherent to all other selection criteria.

4. Bilirubin > 3.0 mg/dl, transaminases > 3 times upper normal limit.

5. Creatinine > 2.0 mg/dl.

6. KPS < 70.

7. Uncontrolled infection.

8. Pregnancy or lactation.

9. Abnormal lung diffusion capacity (DLCO < 40% predicted).

10. Severe cardiovascular disease; New York Heart Association (NYHA) Functional
Classification ≥2.

11. Active CNS disease involvement.

12. Presence of any other malignancy or history of prior malignancy within 5 years of
study entry. Within 5 years, patients treated for Stage I or II cancers are eligible
provided they have a life expectancy > 5 years in relation to this prior malignance.
The 5-year exclusion rule does not apply to-non melanoma skin tumors and in situ
cervical cancer.

13. Pleural effusion or ascites > 1 liter.

14. Known hypersensitivity to rituximab.

15. Psychiatric conditions/disease that impair the ability to give informed consent or to
adequately co-operate.

16. Prior radioimmunotherapy.

17. Prior autologous or allogeneic HSCT.

18. Active evidence of Hepatitis B or C infection; Hepatitis B surface antigen positive.

19. Patients who have had prior radiation to the lung will be excluded from the study,
although mediastinal irradiation will be permitted if minimal lung is in the treatment
volume.

20. Patients who have received >500cGy radiation to the kidneys will be excluded from the
study.